Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Oragenics (OGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oragenics is the larger company by market cap ($2.1 million vs $1.1 million), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | OGEN |
|---|---|---|
| Share price | $0.4801 | $0.463 |
| Market cap | $1.06M | $2.09M |
| 1-day change | -8.17% | 0.00% |
| P/E ratio (TTM) | 0.01 | — |
| EPS (TTM) | $63.74 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.05 | $1.45 |
| 52-week low | $0.473 | $0.46 |
| Distance from 52-week high | -99.08% | -68.07% |
| Analyst consensus | none | — |
| Avg. price target upside | +1755.86% | — |
| Average volume | 3.72M | 29.43K |
| Shares outstanding | 2.20M | 4.51M |
| Employees | 11 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
BDRX vs OGEN FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Oragenics?
Oragenics (OGEN) is larger, with a market capitalization of $2.09M compared with $1.06M for Biodexa Pharmaceuticals American Depositary Shs (BDRX).
Are Biodexa Pharmaceuticals American Depositary Shs and Oragenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.